Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178316 · ClinicalTrials.gov registry record · Phase 2
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT05178316: Completed Phase 2 study, sponsored by Jazz Pharmaceuticals.
NCT05178316 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 282 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (112% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05178316, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
Primary Outcome
Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS-5) is a clinician administered, clinical interview where participants report on their symptoms of PTSD on a scale. The CAPS-5 total score ranges between 0 and 80. Higher scores indicate more severe PTSD symptoms. Change in CAPS-5 total score is being reported, where negative mean scores indicate an improvement in clinical outcome.
Interventions
- DRUG Placebo
- DRUG JZP150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2023-12-05 |
| Phase | Phase 2 |
What the finished NCT05178316 record still lists
NCT05178316 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (112% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05178316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05178316 about?
NCT05178316 is a clinical study titled "A Study of JZP150 in Adults With Posttraumatic Stress Disorder". This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
What is the current status of trial NCT05178316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2021-12-29. Estimated completion is 2023-12-05.
What interventions are being tested in trial NCT05178316?
The interventions under investigation include: Placebo (DRUG), JZP150 (DRUG).
Who is sponsoring clinical trial NCT05178316?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05178316's enrollment target sits among peer trials
282 195th of 2000 higher than 1,805 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI